CN114213424B - 一种呋喃[3，2-b]并吡啶衍生物的合成方法 - Google Patents

一种呋喃[3，2-b]并吡啶衍生物的合成方法 Download PDF

Info

Publication number
CN114213424B
CN114213424B CN202111658903.5A CN202111658903A CN114213424B CN 114213424 B CN114213424 B CN 114213424B CN 202111658903 A CN202111658903 A CN 202111658903A CN 114213424 B CN114213424 B CN 114213424B
Authority
CN
China
Prior art keywords
formula
furan
compound
solvent
synthesizing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202111658903.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN114213424A (zh
Inventor
陆国彪
殷宏飞
金煜东
廖思敏
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hangzhou Gaoguang Pharmaceutical Co ltd
Original Assignee
Hangzhou Aosainuo Biotechnology Co ltd
Hangzhou Gaoguang Pharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hangzhou Aosainuo Biotechnology Co ltd, Hangzhou Gaoguang Pharmaceutical Co ltd filed Critical Hangzhou Aosainuo Biotechnology Co ltd
Priority to CN202111658903.5A priority Critical patent/CN114213424B/zh
Publication of CN114213424A publication Critical patent/CN114213424A/zh
Priority to IL313966A priority patent/IL313966A/en
Priority to PCT/CN2022/139966 priority patent/WO2023125102A1/zh
Priority to KR1020247025635A priority patent/KR20240129021A/ko
Priority to JP2024539899A priority patent/JP2024546195A/ja
Priority to US18/725,431 priority patent/US20250171458A1/en
Priority to CN202280087204.6A priority patent/CN118679166A/zh
Priority to MX2024008276A priority patent/MX2024008276A/es
Priority to CA3244846A priority patent/CA3244846A1/en
Priority to EP22914356.5A priority patent/EP4509509A1/en
Priority to AU2022426316A priority patent/AU2022426316A1/en
Application granted granted Critical
Publication of CN114213424B publication Critical patent/CN114213424B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/69—Two or more oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/58—Pyridine rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
CN202111658903.5A 2021-12-30 2021-12-30 一种呋喃[3，2-b]并吡啶衍生物的合成方法 Active CN114213424B (zh)

Priority Applications (11)

Application Number Priority Date Filing Date Title
CN202111658903.5A CN114213424B (zh) 2021-12-30 2021-12-30 一种呋喃[3，2-b]并吡啶衍生物的合成方法
CN202280087204.6A CN118679166A (zh) 2021-12-30 2022-12-19 1H-呋喃并[3,2-b]咪唑并[4,5-d]吡啶化合物的合成方法
CA3244846A CA3244846A1 (en) 2021-12-30 2022-12-19 PROCESS FOR THE SYNTHESIS OF A 1H-FURO[3,2-B]IMIDAZO[4,5-D]PYRIDINE COMPOUND
KR1020247025635A KR20240129021A (ko) 2021-12-30 2022-12-19 1h-퓨로[3,2-b]이미다조[4,5-d]피리딘 화합물의 합성 방법
JP2024539899A JP2024546195A (ja) 2021-12-30 2022-12-19 １ｈ－フロ［３，２－ｂ］イミダゾ［４，５－ｄ］ピリジン化合物の合成方法
US18/725,431 US20250171458A1 (en) 2021-12-30 2022-12-19 Method for synthesizing 1h-furo[3,2-b]imidazo[4,5-d]pyridine compound
IL313966A IL313966A (en) 2021-12-30 2022-12-19 Methods for synthesizing 1h-furo[3,2-b]imidazo[4,5-d]pyridine compounds
MX2024008276A MX2024008276A (es) 2021-12-30 2022-12-19 Metodos para sintetizar compuestos de 1h-furo[3,2-b]imidazo[4,5-d] piridina.
PCT/CN2022/139966 WO2023125102A1 (zh) 2021-12-30 2022-12-19 1H-呋喃并[3,2-b]咪唑并[4,5-d]吡啶化合物的合成方法
EP22914356.5A EP4509509A1 (en) 2021-12-30 2022-12-19 Method for synthesizing 1h-furo[3,2-b]imidazo[4,5-d]pyridine compound
AU2022426316A AU2022426316A1 (en) 2021-12-30 2022-12-19 Method for synthesizing 1h-furo[3,2-b]imidazo[4,5-d]pyridine compound

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202111658903.5A CN114213424B (zh) 2021-12-30 2021-12-30 一种呋喃[3，2-b]并吡啶衍生物的合成方法

Publications (2)

Publication Number Publication Date
CN114213424A CN114213424A (zh) 2022-03-22
CN114213424B true CN114213424B (zh) 2023-05-26

Family

ID=80707144

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202111658903.5A Active CN114213424B (zh) 2021-12-30 2021-12-30 一种呋喃[3，2-b]并吡啶衍生物的合成方法
CN202280087204.6A Pending CN118679166A (zh) 2021-12-30 2022-12-19 1H-呋喃并[3,2-b]咪唑并[4,5-d]吡啶化合物的合成方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202280087204.6A Pending CN118679166A (zh) 2021-12-30 2022-12-19 1H-呋喃并[3,2-b]咪唑并[4,5-d]吡啶化合物的合成方法

Country Status (10)

Country Link
US (1) US20250171458A1 (https=)
EP (1) EP4509509A1 (https=)
JP (1) JP2024546195A (https=)
KR (1) KR20240129021A (https=)
CN (2) CN114213424B (https=)
AU (1) AU2022426316A1 (https=)
CA (1) CA3244846A1 (https=)
IL (1) IL313966A (https=)
MX (1) MX2024008276A (https=)
WO (1) WO2023125102A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102399848B1 (ko) 2016-10-03 2022-05-19 하이라이트ll 파머슈티컬 (하이난) 컴퍼니, 리미티드 신규한 jak1 선택적 억제제 및 그 용도
CN114213424B (zh) * 2021-12-30 2023-05-26 杭州高光制药有限公司 一种呋喃[3，2-b]并吡啶衍生物的合成方法
WO2025224600A1 (en) * 2024-04-21 2025-10-30 Biohaven Therapeutics Ltd. Treatment of alpha-synucleinopathies and neuroprotection

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007039146A1 (en) * 2005-09-23 2007-04-12 Smithkline Beecham Corporation 4-carboxy pyrazole derivatives as anti-viral agents
WO2011138657A1 (en) * 2010-05-04 2011-11-10 Glenmark Pharmaceuticals S.A. Aryl substituted olefinic compounds as pde10a inhibitors
JP6057907B2 (ja) * 2011-10-04 2017-01-11 株式会社ヤクルト本社 チアゾリジン誘導体又はその塩を有効成分とする医薬品
CN103450125B (zh) * 2013-07-18 2016-01-13 嘉兴中科化学有限公司 一种5-取代苯丙呋喃-2-羧酸及其衍生物的合成方法
EP2940022B1 (en) * 2014-04-30 2020-09-02 Masarykova Univerzita Furopyridines as inhibitors of protein kinases
CN105418620B (zh) * 2014-09-23 2018-05-04 天津药明康德新药开发有限公司 一种4-(叔丁氧羰基)八氢呋喃并[3,2-b]吡啶-6-羧酸的合成方法
WO2016100349A2 (en) * 2014-12-16 2016-06-23 Rugen Holdings (Cayman) Limited Bicyclic azaheterocyclic compounds as nr2b nmda receptor antagonists
WO2016196244A1 (en) * 2015-05-29 2016-12-08 Incyte Corporation Pyridineamine compounds useful as pim kinase inhibitors
CN106432232A (zh) * 2016-09-18 2017-02-22 苏州汉德创宏生化科技有限公司 1‑哌啶‑4‑基‑1,3‑二氢‑咪唑[4,5‑b]吡啶‑2‑酮的合成方法
KR102399848B1 (ko) 2016-10-03 2022-05-19 하이라이트ll 파머슈티컬 (하이난) 컴퍼니, 리미티드 신규한 jak1 선택적 억제제 및 그 용도
CN107216334A (zh) * 2017-06-29 2017-09-29 上海吉尔多肽有限公司 一种6‑氯呋喃[3,2‑b]吡啶的合成方法
CN118619944A (zh) * 2019-06-06 2024-09-10 北京泰德制药股份有限公司 作为atr激酶抑制剂的2,4,6-三取代的嘧啶化合物
KR102785014B1 (ko) 2019-06-06 2025-03-20 항저우 하이라이트엘엘 파마슈티컬 씨오., 엘티디. 푸로이미다조피리딘 화합물의 합성 방법, 푸로이미다조피리딘 화합물의 결정 형태, 및 그의 염의 결정 형태
IL318796A (en) 2019-06-06 2025-04-01 Hangzhou Highlightll Pharmaceutical Co Ltd Method for preparing a furoimidazopyridine compound, polymorph and salt polymorph
CN114213424B (zh) * 2021-12-30 2023-05-26 杭州高光制药有限公司 一种呋喃[3，2-b]并吡啶衍生物的合成方法

Also Published As

Publication number Publication date
CN114213424A (zh) 2022-03-22
WO2023125102A1 (zh) 2023-07-06
CA3244846A1 (en) 2025-06-13
US20250171458A1 (en) 2025-05-29
EP4509509A1 (en) 2025-02-19
CN118679166A (zh) 2024-09-20
KR20240129021A (ko) 2024-08-27
JP2024546195A (ja) 2024-12-17
AU2022426316A1 (en) 2024-07-25
MX2024008276A (es) 2024-09-02
IL313966A (en) 2024-08-01

Similar Documents

Publication Publication Date Title
CN114213424B (zh) 一种呋喃[3，2-b]并吡啶衍生物的合成方法
CN112638870A (zh) 用于制备6-(2,4-二氯苯基)-5-[4-[(3s)-1-(3-氟丙基)吡咯烷-3-基]氧基苯基]-8,9-二氢-7h-苯并[7]轮烯-2-甲酸甲酯的方法
WO2010091877A2 (en) Process for producing ambrisentan
WO2013026391A1 (zh) 嘧菌酯及其合成中专用中间体的合成方法
CN101563312A (zh) 阿塞那平合成中间体的制备方法
CN108623456A (zh) 丁苯酞及其药物中间体的制备方法
CN113234015B (zh) 一种3-酰基二氢喹啉衍生物及其制备方法和应用
CN110003101B (zh) 一种阿帕替尼中间体及其制备方法
CN109232222B (zh) 一种(e)-辛-4-烯-1,8-二酸的制备方法
CN108715576B (zh) 一种3-乙氧基-4-羧基苯乙酸的制备方法
CN115521260B (zh) 一种瑞舒伐他汀叔丁酯的合成方法
CN116693442A (zh) 一种4-甲氧基吡咯衍生物及其合成方法
JP7117796B2 (ja) 化合物並びにブリバラセタム（Ｂｒｉｖａｒａｃｅｔａｍ）の中間体及び原薬の合成におけるその用途
CN101555248B (zh) 一种多取代1,5-萘啶化合物的制备方法
KR101338297B1 (ko) 2,9-디메틸-4,7-디페닐-1,10-페난트롤린의 단일 단계 합성방법
US20160168161A1 (en) Method for producing heterocyclic compound
CN112645886B (zh) 一种尿嘧啶绿色生产工艺
CN116655616B (zh) 一种手性6-羟基吡啶噁唑啉化合物、制备方法及应用
CN116082410B (zh) 一种双齿嘧啶基三氮唑卡宾钯水合3-吡啶磺酸盐化合物及其制备方法和应用
CN110194760B (zh) 制备3-亚苄基-2-（7’-喹啉）-2,3-二氢-异吲哚-1-酮类化合物的方法
JP5250693B2 (ja) カルボン酸化合物の製造方法
US7132544B2 (en) Process for the preparation of tetrasubstituted imidazole derivatives and novel crystalline structures thereof
CN118271351A (zh) 一种2-羟基-4-三氟甲基苯硼酸的制备方法
CN110577520B (zh) 一种6-硝基-4-取代氨基喹唑啉衍生物的制备方法
CN118993997A (zh) 一种3-溴-2-苯基吡啶的制备方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20220822

Address after: Room 301 and 302, Building 4, Hexiang Technology Center, Qiantang District, Hangzhou City, Zhejiang Province, 310018

Applicant after: Hangzhou Gaoguang Pharmaceutical Co.,Ltd.

Address before: 311600 No.18, Fenghe Road, xiaya Town, Jiande City, Hangzhou City, Zhejiang Province

Applicant before: HANGZHOU AOSAINUO BIOTECHNOLOGY CO.,LTD.

TA01 Transfer of patent application right
GR01 Patent grant
GR01 Patent grant